Actively Recruiting
Postoperative Chemotherapy Guided by Circulating Tumor DNA Methylation for High-risk Stage II and III Colorectal Cancer A Multicenter Randomized Phase 3 Study Comparing mFOLFIRINOX and mFOLFOX6XELOX Regimens
Led by Fudan University · Updated on 2024-05-20
340
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Colorectal cancer CRC is a common and serious gastrointestinal cancer with high incidence and mortality worldwide. Early-stage patients have a good survival rate, but high-risk stage II and III patients face lower survival and frequent recurrence. This research evaluates the use of circulating tumor DNA ctDNA methylation to guide postoperative adjuvant chemotherapy in high-risk stage II and III CRC patients, aiming to improve treatment outcomes by tailoring chemotherapy based on ctDNA status. Participants receive one of two chemotherapy regimens mFOLFIRINOX or mFOLFOX6XELOX. Treatment starts with 6 cycles of mFOLFIRINOX every two weeks or 6 cycles of mFOLFOX6 every two weeks or 4 cycles of XELOX every three weeks. After initial chemotherapy, blood tests check ctDNA methylation. If ctDNA remains positive, additional cycles are given if negative, patients receive maintenance chemotherapy with capecitabine every 21 days for 4 cycles. Throughout the study, patients undergo regular plasma ctDNA methylation testing to measure ctDNA clearance rates after 3 and 6 months of chemotherapy. Researchers also monitor disease-free survival, overall survival, adverse events, and treatment completion rates over several years. This multicenter, randomized study involves detailed blood tests, imaging scans, and clinical assessments to evaluate how ctDNA-guided chemotherapy affects patient prognosis and safety over time.
CONDITIONS
Brief Title
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here